← Leaderboards
Michael R Ruff
Creative Bio-Peptides, Inc.
$9,544,819
Attributed
$9,544,819
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.7M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,544,819 · 7
By mechanism
R44$7,774,023 · 3
R43$1,770,796 · 4
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposChemokineReceptorPeptidesOralResponseAnimalsChemokine ReceptorAnimal ModelDosePharmaceutical PreparationsBrainCcr5 GeneRodentPreventBiological MarkersNeuronsPre-ClinicalPathologyDementiaNerve DegenerationCognitive DeficitsCytokineNeuron Loss
Grant awards (10)
A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)$1,118,107
R44 · FY2025 · AG · contact PI
A Synapse-Protecting Small Peptide to Treat a-Syn/Tau Mixed Proteinopathies in Alzheimer's Disease Related Dementias (ADRD)$1,381,306
R44 · FY2024 · AG · contact PI
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD$175,116
R43 · FY2024 · AG · contact PI
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD$324,790
R43 · FY2023 · AG · contact PI
Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder$1,123,774
R44 · FY2022 · DA · contact PI
Development of a Novel Chemokine Receptor Antagonist Peptide as a Non-Opioid Treatment for Relief of Chronic Pain$2,999,505
R44 · FY2021 · NS · contact PI
Development of a Novel Chemokine Receptor Antagonist as a Treatment for Opioid Use Disorder$1,151,331
R44 · FY2021 · DA · contact PI
Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease$499,860
R43 · FY2021 · AG · contact PI
Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's Disease$449,230
R43 · FY2020 · AG · contact PI
A Novel Chemokine Receptor Antagonist to Block Opioid Reinforcement, Relapse and Physical Dependence$321,800
R43 · FY2019 · DA · contact PI